The Filing Desk

aTYR Pharma vs Connect Biopharma

aTYR Pharma ATYR · Connect Biopharma CNTB · Biotechnology

aTYR Pharma reported revenue of $0 million in fiscal 2025, 2.0 times Connect Biopharma's $0 million in fiscal 2025. aTYR Pharma's revenue fell 19.1% in its latest year, and Connect Biopharma's fell 99.8%. aTYR Pharma had an operating margin of -40856.3%, against -90740.6% at Connect Biopharma. Free cash flow was −$62 million at aTYR Pharma and −$52 million at Connect Biopharma.

Side by side

aTYR PharmaConnect Biopharma
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$0M$0M
Revenue growth−19.1%−99.8%
Revenue growth a year, last 5 years−54.7%—
Gross margin——
Operating margin−40,856.3%−90,740.6%
Net margin−39,009.5%−86,687.5%
Free cash flow−$62M−$52M
Free cash flow margin−32,664.7%−80,687.5%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count25.2%0.8%
Last close$3.69$0.63
P/E at the last close——
Insider trades, last 12 monthsbought $50,000, sold $6,293bought $4.4 million, sold $0
Piotroski F-score—1 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
aTYR PharmaConnect Biopharma
Operating margin
Percent of revenue
aTYR PharmaConnect Biopharma
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
aTYR PharmaConnect Biopharma

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the aTYR Pharma and Connect Biopharma pages.